Search for: [Keywords = "the guidelines"]

WIST Guidelines – a chance to make a breakthrough in crisis of the treatment of stroke in Poland

Piotr Musiałek Rafał Niżankowski Adam Witkowski

Nauka | 2023 | No 3 | 145-149 | DOI: 10.24425/nauka.2023.147316

Keywords endovascular stroke mechanical thrombectomy guidelines of WIST

Download PDF Download RIS Download Bibtex

Abstract

This year the new international guidelines of WIST (The World Federation for Interventional Stroke Treatment) on the physician’s training in the interventional acute stroke treatment were published. WIST multispecialty guidelines outline competency and quality standards for physicians and centers to perform safe and effective endovascular stroke treatment with mechanical thrombectomy. The role of quality control and quality assurance is highlighted. WIST establishes an individualized approach to acquiring clinical knowledge and procedural skills to meet the competency requirements for certification of interventionalists of various disciplines and stroke centers in endovascular treatment. WIST guidelines encourage acquisition of skills using innovative training methods such as structured supervised high-fidelity simulation and procedural performance on human perfused cadaveric models. In Poland in 2018 a pilot program on mechanical thrombectomy was established, however endovascular acute stroke treatment is still underused due to limited patients access to stroke centers and too small number of operators.

Go to article

Authors and Affiliations

Piotr Musiałek

1

Rafał Niżankowski

2

Adam Witkowski

3

Klinika Chorób Serca i Naczyń Uniwersytetu Jagiellońskiego,KSS im. Jana Pawła II, Kraków
SanoScience i małopolski konsultant wojewódzki w dziedzinieangiologii, Kraków
Klinika Kardiologii i AngiologiiInterwencyjnej, Narodowy Instytut Kardiologii w Warszawie

Risk assessment for tram traffic on tramway bridges

Kazimierz Jamroz Sławomir Grulkowski Krystian Birr Łukasz Jeliński Marcin Budzyński

Archives of Civil Engineering | 2021 | vol. 67 | No 4 | 39-58 | DOI: 10.24425/ace.2021.138485

Keywords tram infrastructure sections with steep gradients risk assessment design guidelines

Download PDF Download RIS Download Bibtex

Abstract

Promoted by many cities to meet the commute needs of their residents (for work, education, etc.), urban rail transport is a spatially expanding system. The safety of rail passengers and road users is one of the most important factors to consider when designing the infrastructure and assessing the operation of the urban tram system. One of the unsolved issues in the functioning of tram transport are sections of tramways with large longitudinal slopes. The article presents an attempt to use risk management for assessing the operational safety of tramways located on road sections with large longitudinal gradients. This particular problem occurs on a tram route in Gdansk. It runs along a street (partly on an overpass) with a gradient above 5% and a small horizontal curve. Risk was assessed using TRANS-RISK, a risk management method. In the first stage, a risk analysis was carried out using the Bow–Tie methods and error trees. The main risks of serious accidents on the analysed section of the tramway were identified. Three sub-concepts were used to assess risk: individual, societal and collective. Although not generally used for assessments of urban transport infrastructure, the latter was found most useful for assessing the safety of the analysed infrastructure. The results of the analyses and assessments helped to formulate design and maintenance principles for tram infrastructure located on sections with steep gradients.

Go to article

Bibliography

[1] Accident Investigation Board, “Collision of trams on Mäkelänkatu in Helsinki, Finland, on 13 June”, Raport B2/2008R, June 2008.
[2] N. Candappa, B. Corben, and J. Yuen, “Addressing the conflict potential between motor vehicles and trams at cut-through locations”, Monash University Accident Research Centre, Clayton Campus, Victoria, Australia, Report no. 317, 2013.
[3] L. Collis, “Cross-industry working group on freight derailment bowtie risk analysis report”, RSBB – Rail Safety and Standards Board, Report no. RSSB/P1500134/RSK/RPT/00001 Rev 1.0, 2016.
[4] Department for Transport, “Derailment of a tram at Pomona, Manchester 17 January 2007”, The Rail Accident Investigation Branch, Report 09/2008, UK, 2008.
[5] V. De Labonnefonm and J.M. Passelaigue, “Analysis of reported events – year 2012 – evolution 2004–2012”, Tram Division, Ministère de l’Écologie, de l’Énergie, Paris, 2014.
[6] S. Dindar et al., “Derailment-based fault tree analysis on risk management of railway turnout systems”, IOP Conference Series: Materials Science and Engineering, vol. 245, no. 4, 2017. DOI: 10.1088/1757- 899X/245/4/042020.
[7] “Największa katastrofa tramwajowa w historii Polski wydarzyła się w Szczecinie, 48 rocznica”, Gazeta Wyborcza. pl, 07 grudzien 2015.
[8] K. Jamroz, et al., “Trans-Risk – An integrated method for risk management in transport”, Journal of KONBiN, vol. 1, no. 13, 2010. DOI: 10.2478/v10040-008-0149-9.
[9] K. Jamroz, “Metoda zarz˛adzania ryzykiem w inzynierii drogowej” (in Polish), “Method of risk management in highway engineering”, Wydawnictwo Politechnika Gdanskiej, Gdansk, Poland, 2011.
[10] K. Jamroz, et al., “Analiza i ocena bezpieczenstwa ruchu tramwajowego na estakadzie tramwajowej w ulicy Rakoczego w Gdansku”, Raport, Politechnika Gdanska, Fundacja Rozwoju Inzynierii Lądowej, Gdansk 2015.
[11] K. Jamroz, et al., “Audyt bezpieczenstwa ruchu tramwajowego w Gdansku w ramach zadania, Dokumentacja dla przyszłych projektów”, Raport, Fundacja Rozwoju Inzynierii L˛adowej, Transprojekt Gdanski, TRAFIK, Gdansk 2017.
[12] A Kadzinski, “Studium wybranych aspektów niezawodnosci systemów oraz obiektów pojazdów szynowych”, Politechnika Poznanska, Rozprawy nr 511, Poznan 2013.
[13] A. Kobaszynska-Twardowska, “Zarządzanie ryzykiem zagrozeń na przejazdach kolejowych”, Praca doktorska, WydziałMaszyn Roboczych i Transportu, Politechnika Poznanska, Poznan 2017.
[14] A. Kobaszynska-Twardowska, et al., “Methodology of research on drivers at level crossings”, 12th International Road Safety Conference GAMBIT 2018, Gdansk, Poland MATEC Web of Conferences, vol. 231, 2018. DOI: 10.1051/matecconf/201823101011.
[15] “The tram accident in Gothenburg”, Report 62, KOMEDO: March 12, 1992.
[16] Z. Konopacki-Maciuk, “Trams as tools of urban transformation in French cities”, Technical Transactions Architecture, vol. 10-A, 2014.
[17] L. Menetrieux, “Tram accidents’ analysis – France”, STRMTG, French Guided Transport Technical Service –Ministère de l’Écologie, de l’Énergie, Paris 2011.
[18] RAIB, “Rail accident report: Overturning of a tram at Sandilands junction”, Croydon 9 December 2016. Report 18/2017, December 2017.
[19] NSW Government: Transport Roads and Traffic Authority, “Railway crossing safety series. Evaluate: Applying the railway crossing cause consequence bow tie models”, RTA/Pub. 11.377, Roads and Traffic Authority of New South Wales, Australia, 2011.
[20] J. Szmaglinski, S. Grulkowski, and K. Birr, “Identification of safety hazards and their sources in tram transport”, 12th International Road Safety Conference GAMBIT 2018, Gdansk, Poland MATEC Web of Conferences, vol. 231, 2018. DOI: 10.1051/matecconf/201823105008.
[21] V. Trbojevic, “Risk criteria in EU. Advances in safety and reliability”, Taylor and Francis Group, London 2005.
[22] X. Liu, P.L.Ch. Barkan, and M.R. Saat, “Analysis of derailments by accident cause: evaluating railroad track upgrades to reduce transportation risk”, Transportation Research Record: Journal of the Transportation Research Board, no. 2261, Transportation Research Board of the National Academies, Washington, D.C., pp. 178–185, 2011. DOI: 10.3141/2261-21.
[23] A. Kahlouche and R. Chaib, “Analysis of the tram safety: case study of Algeria”, Procedia Engineering, vol. 178, pp. 401–408, 2017. DOI: 10.1016/j.proeng.2017.01.076.
[24] M. Schmitz, Ch. Hessel, and U. Stahlberg, “Operation of autonomous tramways”, Verband Deutscher Verkehrsunternehmen e. V.(VDV), Position paper, Cologne, Germany, August 2019.
[25] M. Teixeira, J. Baptista, and C. Gaïvoto, “Operation and safety of tramways in interaction with public space”, COST – European Cooperation in Science and Technology, TU1103 Action final report, September 2015.

Go to article

Authors and Affiliations

Kazimierz Jamroz

1

e-mail:

ORCID:

Sławomir Grulkowski

1

Krystian Birr

1

e-mail:

ORCID:

Łukasz Jeliński

1

e-mail:

ORCID:

Marcin Budzyński

1

e-mail:

ORCID:

Gdansk University of Technology, Faculty of Civil and Environmental Engineering, Narutowicza 11/12, 80-233 Gdansk, Poland

Environmental Damage under the CLC 92 and Fund 92 Conventions. Remarks Concering New Guidelines for Presenting Claims for Environmental Damage

Zuzanna Pepłowska-Dąbrowska

Prawo Morskie | 2018 | No XXXIV | 211-224 | DOI: 10.24425/pm.2018.125833

Keywords environmental damage oil pollution CLC 1992 IOPC Funds the guidelines lost services alternative environment "Erika" " Prestige"

Download PDF Download RIS Download Bibtex

Abstract

This article aims to discuss the notion of environmental damage under the CLC 1992 and FUND 1992 as stated in the new Guidelines for Presenting Claims for Environmental Damage prepared by the International Oil Pollution Compensation Funds. That approach is contrasted with the solution adopted in the United States of America under the OPA. Particular attention is given to the problems of compensation for lost services of the environment, as well as providing alternative environment as a restoration measure. The judgments of French and Spanish courts in the Erika and Prestige cases are discussed, raising questions as to suitability of the CLC 1992/FUND 1992 system.

Go to article

Authors and Affiliations

Zuzanna Pepłowska-Dąbrowska

Study on the distribution of SAR and temperature in human brain during radio-frequency cosmetic treatment

Xinzhe Qi Mai Lu

Archives of Electrical Engineering | 2021 | vol. 70 | No 1 | 115-127 | DOI: 10.24425/aee.2021.136056

Keywords electromagnetic exposure human head model ICNIRP guidelines radiofrequency cosmetic instruments safety assessment

Download PDF Download RIS Download Bibtex

Abstract

This paper established a radio-frequency electrode model and human head model used in RF cosmetic instruments. The distribution of electric field strength, a specific absorption rate (SAR), and temperature distribution in the human brain at 1 MHz and 6 MHz were studied and the results compared with the International Commission on Nonionizing Radiation Protection (ICNIRP) guidelines. The results showed that under those two frequencies the maximum value of electric field strength in the human brain was 1.52 V/m and it was about 5.4% of the ICNIRP basic restrictions, the maximum SAR in human brain was about 2:21 ? 10??3 W/kg, which was far less than 2 W/kg of ICNIRP basic restrictions, the maximum temperature of the human brainwas 37:6? located in thewounded skin, which was the same as the normal temperature 37?. Since all the results were within the ICNIRP basic restrictions, the electromagnetic exposure generated by the RF cosmetic electrode will not pose a threat to the human health.

Go to article

Bibliography

[1] Bidi M., Biological risk assessment of high-voltage transmission lines on worker’s health of electric society, Archives of Electrical Engineering, vol. 69, no. 1, pp. 57–68 (2020).
[2] Deltuva R., Lukocius R., Electric and magnetic field of different transpositions of overhead power line, Archives of Electrical Engineering, vol. 66, no. 3, pp. 595–605 (2017).
[3] Alam M., Levy R., Pajvani U., Ramierez A., Guitart J., Veen H., Gladstone B., Safety of radiofrequency treatment over human skin previously injected with medium-term injectable soft-tissue augmentation materials: a controlled pilot trial, Lasers in Surgery and Medicine, vol. 39, no. 5, pp. 468–468 (2007).
[4] Suh D.H., Byun J.E., Lee J.S., Song Y.K., Kim S.H., Clinical efficacy and safety evaluation of a novel fractional unipolar radiofrequency device on facial tightening: A preliminary report, Journal of Cosmetic Dermatology, vol. 16, no. 2, pp. 199–204 (2017).
[5] Lee S.H., Lee D.H., Won C.H., Chang H.W., Kwon H.H., Kim K.H., Chung J.H., Fractional rejuvenation using a novel bipolar radiofrequency system in Asian skin, Dermatol Surgery, vol. 37, no. 11, pp. 1611–1619 (2011).
[6] International Commission on Non-ionizing Radiation Protection Guidelines for limiting exposure to time-varying electric and magnetic fields (up to 300GHz), Health Physics, vol. 74, no. 4, pp. 494–522 (1998).
[7] Alhalabi S.M., Agha O.Q., Hantash B.M., Nonablative radiofrequency for skin rejuvenation: a review of the literature, Expert Review of Dermatology, vol. 7, no. 7, pp. 589–599 (2012).
[8] Sadick N., Tissue tightening technologies: Fact or fiction, Aesthetic Surgery Journal, vol. 28, no. 2, pp. 180–188 (2008).
[9] Nelson A., Beynet D., Lask G., A novel non-invasive radiofrequency dermal heating device for skin tightening of the face and neck, Journal of Cosmetic and Laser Therapy, vol. 17, no. 6, pp. 1–6 (2015).
[10] Friedman J., Gilead L., The Use of Hybrid Radiofrequency Device for the Treatment of Rhytids and Lax Skin, Dermatologic Surgery, vol. 33, no. 5, pp. 547–551 (2007).
[11] Brightman L., Goldman MP., Taub A.F., Sublative Rejuvenation: Experience with a New Fractional Radiofrequency System for Skin Rejuvenation and Repair, Journal of Drugs in Dermatology, vol. 8, no. 11, pp. 9–13 (2009).
[12] Hsu T.S., Kaminer M.S., The use of nonablative radiofrequency technology to tighten the lower face and neck, Seminars in Cutaneous Medicine and Surgery, vol. 22, no. 2, pp. 1–123 (2003).
[13] Rush S., Driscoll D.A., EEG electrode sensitivity–an application of reciprocity, IEEE Transactions on Biomedical Engineering, vol. 16, no. 1, pp. 15–22 (1968).
[14] Huclova S., Baumann D., Talary M., Frohlich J., Sensitivity and specificity analysis of fringing-field dielectric spectroscopy applied to a multi-layer system modelling the human skin, Physics in Medicine and Biology, vol. 56, no. 24, pp. 7777–7793 (2011).
[15] Gabriel C., Bentall R., Grant E.H., Comparison of the dielectric properties of normal and wounded human skin material, Bioelectromagnetics, vol. 8, no. 1, pp. 23–27 (1987).
[16] Huclova S., Erni D., Frohlich J., Modelling and validation of dielectric properties of human skin in the MHz region focusing on skin layer morphology and material composition, Journal of Physics D Applied Physics, vol. 45, no. 45 (2012), DOI: 10.1088/0022-3727/45/2/025301.
[17] Cole K., Cole R., Dispersion and absorption in dielectrics: I. Alternating current characteristics, Journal of Chemical Physics, vol. 9, no. 4, pp. 341–351 (1941).
[18] http://www.itis.ethz.ch/database.pl, accessed January 2020.
[19] http://cn.comsol.com/pl, accessed January 2020.
[20] Rush S., Driscoll D.A., Current distribution in the brain from surface electrodes, Anesthesia and Analgesia, vol. 47, no. 6, pp. 717–723 (1968).
[21] Tamnes K., Ostby Y., Fjell A.M., Westlye L.T., Due P., Walhovd K., Brain maturation in adolescence and young adulthood: regional age-related changes in cortical thickness and white matter volume and microstructure, Cerebral Cortex, vol. 20, no. 3, pp. 534–548 (2010).
[22] Gabriel S., Lau W., Gabriel C., The dielectric properties of biological tissues: III parametric models for the dielectric spectrum of tissues, Physics in Medicine and Biology, vol. 41, no. 11, pp. 2271–2293 (1996).
[23] Hruza G., Taub F., Collier S., Mulholland R., Skin rejuvenation and wrinkle reduction using a fractional radiofrequency system, Journal of Drugs in Dermatology, vol. 8, no. 3, pp. 259–265 (2009).

Go to article

Authors and Affiliations

Xinzhe Qi

1

Mai Lu

1

e-mail:

ORCID:

Key Laboratory of Opt-Electronic Technology and Intelligent Control of Ministry of Education, Lanzhou Jiaotong University, Lanzhou, 730070, Gansu Province, P.R. China

Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice — one center study

Patrycja Cecha Anna Chromik Ilona Piotrowska Michał Zabojszcz Magdalena Dolecka-Ślusarczyk Zbigniew Siudak

Folia Medica Cracoviensia | 2021 | Vol. 61 | No 3 | 43-54 | DOI: 10.24425/fmc.2021.138950

Keywords cardiovascular risk ESC/EAS guidelines lipid-lowering therapy PCSK9 inhibitors statins

Download PDF Download RIS Download Bibtex

Abstract

Background: Cardiovascular diseases are the first cause of death globally. Hypercholester-olemia is the most important factor responsible for atherosclerotic plaque formation and increasing cardiovascular risk. Reduction of LDL-C level is the most relevant goal for reduction of cardiovascular risk.
Aims: Real life adherence to guidelines concerning statin therapy in one center study population. Methods: We analyzed data collected in the Department of Internal Diseases from September 2019 to February 2020, obtained from 238 patients hospitalized in this time period. We assessed application of the new 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias in daily clinical practice and compared effectiveness of LLT according to 2016 and 2019 guidelines.
Results: Only 1 in 5 patients with dyslipideamia achieve the 2019 ESC/EAS guideline-recommended levels of LDL-C with relation to their TCVR. We noticed that 20 of patients who did not achieve proper 2019 LDL level, meet the therapy targets established in year 2016. We observed that higher patient TCVR resulted in better compliance with guidelines and ordination of proper LLT. Most patients were on monotherapy with statins.
Conclusions: It could be beneficial to start treatment with double or even triple therapy especially in group with the highest LDL-C levels.

Go to article

Bibliography

1. Cardiovascular diseases. Available from: https://www.who.int/health-topics/cardiovascular-diseases/ #tab=tab_1
2. Poland | Institute for Health Metrics and Evaluation [Internet]. Available from: http://www.healthdata.org/poland
3. Ference B.A., Ginsberg H.N., Graham I., et al.: Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38 (32): 2459–2472.
4. Navarese E.P., Robinson J.G., Kowalewski M., et al.: Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering a systematic review and meta-analysis. JAMA. 2018; 319 (15): 1566–1579.
5. Zdrojewski T., Solnica B., Cybulska B., et al.: Prevalence of lipid abnormalities in Poland. the NATPOL 2011 survey. Kardiol Pol. 2016; 74 (3): 213–223.
6. Pająk A., Szafraniec K., Polak M., et al.: Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: The WOBASZ study. Pol Arch Med Wewn. 2016; 126 (9): 642–652.
7. Mach F., Baigent C., Catapano A.L., et al.: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Vol. 41, European Heart Journal. 2020. p. 111–188.
8. Catapano A.L., Graham I., De Backer G., et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37: 2999–3058.
9. Baigent C., Blackwell L., Emberson J., et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376 (9753): 1670–1681.
10. Silverman M.G., Ference B.A., Im K., et al.: Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. 2016; 316 (12): 1289–1297.
11. Giugliano R.P., Pedersen T.R., Park J.G., et al.: Clinical efficacy and safety of achieving very low LDL- cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28; 390 (10106): 1962–1971.
12. Soran H., Dent R., Durrington P.: Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017; 106 (4): 237–248.
13. Masana L., Girona J., Ibarretxe D., et al.: Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels — The zero-LDL hypothesis. J Clin Lipidol. 2018; 12 (2): 292–299. e3.
14. Katzmann J.L., Sorio-Vilela F., Dornstauder E., et al.: Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin / ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. 2020; (0123456789).
15. Guglielmi V., Bellia A., Pecchioli S., et al.: Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Atherosclerosis. 2017; 263: 36–41.
16. Kaddoura R., Orabi B., Salam A.M.: Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update. J Drug Assess. 2020; 9 (1): 129–144.
17. Saborowski M., Dölle M., Manns M.P., et al.: Lipid-lowering therapy with pcsk9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort. Cardiol J. 2018; 25 (1): 32–41.
18. Novel Drug Approvals for 2015 | FDA [Internet]. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-ap-provals-2015
19. Zodda D., Giammona R., Schifilliti S.: Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy. 2018; 6 (1): 10.
20. Szymański F.M., Barylski M., Cybulska B., et al.: Recommendation for the management of dyslipidemia in Poland — Third declaration of sopot. Interdisciplinary expert position statement endorsed by the Polish cardiac society working group on cardiovascular pharmacotherapy. Cardiol J. 2018; 25 (6): 655–665.
21. Koskinas K.C., Windecker S., Pedrazzini G., et al.: Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019 Nov 19; 74 (20): 2452–62.
22. Sabatine M.S., Giugliano R.P., Keech A.C., et al.: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; 376 (18): 1713–1722.
23. Murphy S.A., Pedersen T.R., Gaciong Z.A., et al.: Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients with Cardiovascular Disease: A Prespecified Analysis from the FOURIER Trial. JAMA Cardiol. 2019; 4 (7): 613–619.
24. Bittner V.A., Szarek M., Aylward P.E., et al.: Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020; 75 (2): 133–144.
25. Schwartz G.G., Steg P.G., Szarek M., et al.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379 (22): 2097–2107.
26. Raal F.J., Kallend D., Ray K.K., et al.: Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020 Apr 16; 382 (16): 1520–1530.
27. Ferri N., Corsini A.: Clinical Pharmacology of Statins: an Update. Curr Atheroscler Rep. 2020 Jun 3; 22 (7): 26.
28. Ballantyne C.M., Banach M., Mancini G.B.J., et al.: Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018; 277: 195–203.
29. Banach M., Duell P.B., Gotto A.M., et al.: Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholester-olemia. JAMA Cardiol. 2020; 1–11.
30. Kam N., Perera K., Zomer E., et al.: Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis. Pharmacoeconomics. 2020; 38 (9): 1007–1020.

Go to article

Authors and Affiliations

Patrycja Cecha

1

Anna Chromik

1

Ilona Piotrowska

1

Michał Zabojszcz

1

Magdalena Dolecka-Ślusarczyk

1

Zbigniew Siudak

1

Collegium Medicum, Jan Kochanowski University, Kielce, Poland

Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes — a minireview

Ewa Wieczorek-Surdacka Andrzej Surdacki Jolanta Świerszcz Bernadeta Chyrchel

Folia Medica Cracoviensia | 2020 | Vol. 60 | No 4 | 97-101 | DOI: 10.24425/fmc.2020.136207

Keywords sodium-glucose cotransporter-2 inhibitors glucagon-like peptide-1 receptor agonists renoprotection diabetic kidney disease type 2 diabetes cardiovascular outcome trials clinical practice guidelines

Download PDF Download RIS Download Bibtex

Abstract

Intensive hypoglycemic treatment is the strongest preventive strategy against the development of microvascular complications of type 2 diabetes (T2DM), including diabetic nephropathy. However, some antidiabetic drugs, i.e. sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have an additional renoprotective effect beyond glucose control by itself. Similar, both SGLT-2i and GLP1-RA have been demonstrated to decrease the risk of adverse cardiovascular (CV) events in CV outcome trials. Nevertheless, there are relevant differences in CV and renal effects of SGLT-2i and GLP1-RA. First, SGLT2i reduced the incidence and progression of albuminuria and prevented loss of kidney function, while predominant renal benefits of GLP1-RA were driven by albuminuria outcomes. Second, the risk of heart failure (HF) hospitalizations decreased on SGLT2i but not on GLP1-RA, which gives priority to SGLT2i in T2DM and HF, especially with depressed EF. Third, either GLP1-RA (reducing predominantly atherosclerosis-dependent events) or SGLT-2i, should be used in T2DM and established atherosclerotic CV disease (ASCVD) or other indicators of high CV risk. In this review, we have briefly compared clinical practice guidelines of the American Diabetes Association (2020 and 2021 versions), Polish Diabetes Association (2020) and the European Society of Cardiology/European Association for the Study of Diabetes (2019), with a focus on the choice between SGLT-2i and GLP1-RA in patients with diabetic kidney disease.

Go to article

Bibliography

1. American Diabetes Association: Microvascular complications and foot care: Standards of Medical Care in Diabetes-2021. Standards of Medical Care in Diabetes–2020. Diabetes Care. 2020; 43 (Suppl 1): S135–S151.
2. American Diabetes Association: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43 (Suppl 1): S98–S110.
3. American Diabetes Association: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021; 44 (Suppl 1): S111–S124.
4. Williams D.M., Nawaz A., Evans M.: Renal outcomes in type 2 diabetes: A review of cardiovascular and renal outcome trials. Diabetes Ther. 2020; 11: 369–386.
5. Heerspink H.J.L., Stefánsson, B.V., Correa-Rotter, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383: 1436–1446.
6. Jhund P.S., Solomon S.D., Docherty K.F., et al.: Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of DAPA-HF. Circulation 2020 Oct 12; doi: 10.1161/CIRCULATIONAHA.120.050391.
7. Packer M., Anker S.D., Butler J., et al.: Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413–1424.
8. American Diabetes Association: Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019; 42 (Suppl 1): S90–S102.
9. Diabetes Poland (Polish Diabetes Association): 2020 Guidelines on the management of diabetic patients: A position of Diabetes Poland. Clin Diabetol. 2020; 9: 1–101.
10. Cosentino F., Grant P.J., Aboyans V., et al.: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41: 255–323.

Go to article

Authors and Affiliations

Ewa Wieczorek-Surdacka

1

Andrzej Surdacki

2

Jolanta Świerszcz

3

Bernadeta Chyrchel

4

Chair and Department of Nephrology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
Second Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
Department of Medical Education, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland
Second Department of Cardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland

Search results

Filters

Search results

WIST Guidelines – a chance to make a breakthrough in crisis of the treatment of stroke in Poland

Abstract

Authors and Affiliations

Risk assessment for tram traffic on tramway bridges

Abstract

Bibliography

Authors and Affiliations

Environmental Damage under the CLC 92 and Fund 92 Conventions. Remarks Concering New Guidelines for Presenting Claims for Environmental Damage

Abstract

Authors and Affiliations

Study on the distribution of SAR and temperature in human brain during radio-frequency cosmetic treatment

Abstract

Bibliography

Authors and Affiliations

Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice — one center study

Abstract

Bibliography

Authors and Affiliations

Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes — a minireview

Abstract

Bibliography

Authors and Affiliations